
Keywords: basal cell carcinoma; burden; costs; healthcare utilization; treatment; aBCC; advanced basal cell carcinoma; FDA; Food and Drug Administration; ICD-9-CM; International Classification of Diseases, Ninth Revision, Clinical Modification; laBCC; locally advan